44 research outputs found
Measurement of the Charged Multiplicities in b, c and Light Quark Events from Z0 Decays
Average charged multiplicities have been measured separately in , and
light quark () events from decays measured in the SLD experiment.
Impact parameters of charged tracks were used to select enriched samples of
and light quark events, and reconstructed charmed mesons were used to select
quark events. We measured the charged multiplicities:
,
, from
which we derived the differences between the total average charged
multiplicities of or quark events and light quark events: and . We compared
these measurements with those at lower center-of-mass energies and with
perturbative QCD predictions. These combined results are in agreement with the
QCD expectations and disfavor the hypothesis of flavor-independent
fragmentation.Comment: 19 pages LaTex, 4 EPS figures, to appear in Physics Letters
Precision measurement of the deuteron spin structure function
We report on a high-statistics measurement of the deuteron spin structure function g[sup d][sub 1] at a beam energy of 29 GeV in the kinematic range 0.029 < x < 0.8 and 1 < Q2 < 10 (GeV/c)2. The integral Gamma [sup d][sub 1] = (integral)[sup 1][sub 0]g[sup d][sub 1]dx evaluated at fixed Q2 = 3 (GeV/c)2 gives 0.042 ± 0.003(stat) ± 0.004(syst). Combining this result with our earlier measurement of g[sup p][sub 1], we find Gamma [sup p][sub 1]- Gamma [sup n][sub 1] = 0.163 ± 0.010(stat) ± 0.016(syst), which agrees with the prediction of the Bjorken sum rule with O( alpha [sup 3][sub s]) corrections, Gamma [sup p][sub 1]- Gamma [sup n][sub 1] = 0.171 ± 0.008. We find the quark contribution to the proton helicity to be Delta q = 0.30 ± 0.06
Measurements of R=sigma_L/sigma_T for 0.03<x<0.1 and Fit to World Data
Measurements were made at SLAC of the cross section for scattering 29 GeV
electrons from carbon at a laboratory angle of 4.5 degrees, corresponding to
0.03<x<0.1 and 1.3<Q^2<2.7 GeV^2. Values of R=sigma_L/sigma_T were extracted in
this kinematic range by comparing these data to cross sections measured at a
higher beam energy by the NMC collaboration. The results are in reasonable
agreement with pQCD calculations and with extrapolations of the R1990
parameterization of previous data. A new fit is made including these data and
other recent results.Comment: 8 pages, 4 figures, late
Dynamic analysis of drug-induced cytotoxicity using chip-based dielectrophoretic cell immobilization technology
Quantification of programmed and accidental cell death provides useful end-points for the anticancer drug efficacy assessment. Cell death is, however, a stochastic process. Therefore, the opportunity to dynamically quantify individual cellular states is advantageous over the commonly employed static, end-point assays. In this work, we describe the development and application of a microfabricated, dielectrophoretic (DEP) cell immobilization platform for the real-time analysis of cancer drug-induced cytotoxicity. Microelectrode arrays were designed to generate weak electro-thermal vortices that support efficient drug mixing and rapid cell immobilization at the delta-shape regions of strong electric field formed between the opposite microelectrodes. We applied this technology to the dynamic analysis of hematopoietic tumor cells that represent a particular challenge for real-time imaging due to their dislodgement during image acquisition. The present study was designed to provide a comprehensive mechanistic rationale for accelerated cell-based assays on DEP chips using real-time labeling with cell permeability markers. In this context, we provide data on the complex behavior of viable vs dying cells in the DEP fields and probe the effects of DEP fields upon cell responses to anticancer drugs and overall bioassay performance. Results indicate that simple DEP cell immobilization technology can be readily applied for the dynamic analysis of investigational drugs in hematopoietic cancer cells. This ability is of particular importance in studying the outcome of patient derived cancer cells, when exposed to therapeutic drugs, as these cells are often rare and difficult to collect, purify and immobilize